Key facts
- Stylus Medicine’s last known valuation is $114.0M (May 2025).
- It has raised $93.0M across 1 recorded rounds; the latest was Early Stage VC (Series A) ($85.0M) in May 2025.
- Notable investors include Khosla Ventures, RA Capital Management, University of California, Johnson & Johnson JJDC, Brainstorm Ventures — 12 tracked in total.
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Stylus Medicine
Funding rounds
1 roundsAbout Stylus Medicine
Developer of in vivo genetic medicines designed to enable precise insertion of therapeutic genetic material within the human genome. The company offers engineered recombinase technology, targeted lipid nanoparticle delivery, and gene integration capabilities for complex therapeutic payloads, enabling healthcare and biotechnology researchers to develop treatments for oncology, autoimmune, and genetic diseases.
- Industry
- Drug Discovery
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2022
- Employees
- 40
- Website
- stylusmedicine.com/
- Ownership
- Privately Held (backing)
Stylus Medicine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Stylus Medicine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Stylus Medicine in its N-PORT filings yet. We sweep new filings monthly.